Q32 Bio (QTTB) Competitors $2.97 +0.17 (+6.07%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$2.88 -0.09 (-2.86%) As of 10/24/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QTTB vs. SXTC, MIST, MCRB, CGEN, ELDN, CCCC, THTX, PEPG, MOLN, and NKTXShould you be buying Q32 Bio stock or one of its competitors? The main competitors of Q32 Bio include China SXT Pharmaceuticals (SXTC), Milestone Pharmaceuticals (MIST), Seres Therapeutics (MCRB), Compugen (CGEN), Eledon Pharmaceuticals (ELDN), C4 Therapeutics (CCCC), Theratechnologies (THTX), PepGen (PEPG), Molecular Partners (MOLN), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry. Q32 Bio vs. Its Competitors China SXT Pharmaceuticals Milestone Pharmaceuticals Seres Therapeutics Compugen Eledon Pharmaceuticals C4 Therapeutics Theratechnologies PepGen Molecular Partners Nkarta China SXT Pharmaceuticals (NASDAQ:SXTC) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings. Does the media prefer SXTC or QTTB? In the previous week, China SXT Pharmaceuticals had 1 more articles in the media than Q32 Bio. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 2 mentions for Q32 Bio. China SXT Pharmaceuticals' average media sentiment score of 1.10 beat Q32 Bio's score of 0.52 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China SXT Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Q32 Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, SXTC or QTTB? China SXT Pharmaceuticals has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Q32 Bio has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Which has preferable valuation & earnings, SXTC or QTTB? China SXT Pharmaceuticals has higher revenue and earnings than Q32 Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina SXT Pharmaceuticals$1.74M89.36-$3.30MN/AN/AQ32 BioN/AN/A-$47.73M-$4.30-0.69 Do analysts rate SXTC or QTTB? Q32 Bio has a consensus target price of $12.17, indicating a potential upside of 309.65%. Given Q32 Bio's stronger consensus rating and higher possible upside, analysts clearly believe Q32 Bio is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Q32 Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11 Is SXTC or QTTB more profitable? China SXT Pharmaceuticals' return on equity of 0.00% beat Q32 Bio's return on equity.Company Net Margins Return on Equity Return on Assets China SXT PharmaceuticalsN/A N/A N/A Q32 Bio N/A -2,709.70%-61.16% Do insiders & institutionals believe in SXTC or QTTB? 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Comparatively, 40.0% of Q32 Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryChina SXT Pharmaceuticals beats Q32 Bio on 7 of the 12 factors compared between the two stocks. Get Q32 Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QTTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QTTB vs. The Competition Export to ExcelMetricQ32 BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.23M$3.46B$6.22B$10.81BDividend YieldN/A2.28%5.72%4.80%P/E Ratio-0.698.7521.9925.53Price / SalesN/A497.20592.72133.12Price / CashN/A46.9537.2561.86Price / Book6.3210.4012.056.61Net Income-$47.73M-$52.83M$3.34B$277.10M7 Day Performance-6.31%2.10%1.93%2.57%1 Month Performance57.98%12.33%7.77%3.79%1 Year Performance-94.13%14.14%56.40%33.01% Q32 Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QTTBQ32 Bio2.6575 of 5 stars$2.97+6.1%$12.17+309.7%-93.8%$36.23MN/A-0.6939SXTCChina SXT Pharmaceuticals1.0462 of 5 stars$1.45-1.9%N/A-72.3%$171.49M$1.74M0.0090News CoverageAnalyst ForecastGap UpMISTMilestone Pharmaceuticals2.8762 of 5 stars$1.99flat$4.50+126.1%+31.5%$169.14M$1M-2.3730Analyst ForecastGap UpMCRBSeres Therapeutics1.9826 of 5 stars$19.23+0.6%$14.33-25.5%+25.7%$167.39M$126.32M-4.18330Analyst ForecastGap UpCGENCompugen1.7712 of 5 stars$2.24+21.1%$4.00+78.6%+4.7%$165.09M$27.86M-10.1870News CoverageAnalyst ForecastGap UpHigh Trading VolumeELDNEledon Pharmaceuticals2.199 of 5 stars$2.72-0.7%$10.00+267.6%-1.7%$164.08MN/A-2.3210Analyst ForecastGap UpCCCCC4 Therapeutics3.2395 of 5 stars$2.11-6.2%$8.50+302.8%-58.8%$160.13M$35.58M-1.34150News CoverageUpcoming EarningsAnalyst ForecastGap UpTHTXTheratechnologiesN/A$3.42+0.9%N/A+173.5%$157.21M$84.38M-17.99140High Trading VolumePEPGPepGen3.3298 of 5 stars$4.55-3.6%$8.40+84.6%-44.5%$154.65MN/A-1.5430Positive NewsAnalyst ForecastMOLNMolecular Partners1.6367 of 5 stars$3.87+1.7%$8.00+107.0%-40.4%$153.42M$5.65M-1.86180News CoverageUpcoming EarningsNKTXNkarta2.6468 of 5 stars$2.26+4.6%$13.50+497.3%-33.8%$153.41MN/A-1.53140News CoverageAnalyst Upgrade Related Companies and Tools Related Companies China SXT Pharmaceuticals Competitors Milestone Pharmaceuticals Competitors Seres Therapeutics Competitors Compugen Competitors Eledon Pharmaceuticals Competitors C4 Therapeutics Competitors Theratechnologies Competitors PepGen Competitors Molecular Partners Competitors Nkarta Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QTTB) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
